Infliximab biosimilar (Reliance Life Sciences)

英夫利西单抗生物类似药 (Reliance Life Sciences)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameInfliximab biosimilar (Reliance Life Sciences)
Drug Alias Name英利昔单抗生物仿制药 (Reliance Life Sciences)InfimabBOW-015R-TPR-015
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIndia
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesEpirus Biopharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesMabxience Sa
Inactive CompaniesEpirus Biopharmaceuticals (Switzerland) Gmbh
Active IndicationsArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeL04AB02
Related LinksN/A